Serdexmethylphenidate/dexmethylphenidate

From Wikipedia, the free encyclopedia
Not to be confused with serdexmethylphenidate.

Serdexmethylphenidate/dexmethylphenidate
Serdexmethylphenidate 2D Structure.svg
Dexmethylphenidate structure.svg
Combination of
SerdexmethylphenidateCatecholamine reuptake inhibitor
DexmethylphenidateCatecholamine reuptake inhibitor
Clinical data
Trade namesAzstarys
Other namesKP415
AHFS/Drugs.comAzstarys
License data
ATC code
  • None
Legal status
Legal status
  • US: Schedule II [1]
Identifiers
KEGG

Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate and dexmethylphenidate which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older.[2][3]

It was approved for medical use in the United States in March 2021.[2]

References[]

  1. ^ "Azstarys- serdexmethylphenidate and dexmethylphenidate capsule". DailyMed. Retrieved 13 July 2021.
  2. ^ a b "KemPharm Announces FDA Approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD" (Press release). KemPharm. 3 March 2021. Retrieved 3 March 2021 – via GlobeNewswire.
  3. ^ McCuistion LE, Yeager JJ, Winton MB, DiMaggio K (2021). "Chapter 18: Stimulants". Pharmacology E-Book: A Patient-Centered Nursing Process Approach. St. Louis, MO: Elsevier Health Sciences. p. 203. ISBN 978-0-323-79316-2.

External links[]


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""